ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 17

Kappa-Deleting Recombination Excision Circles (KREC) in B Cells and Serum B Cell Activating Factor (BAFF): Possible Aids in Predicting Juvenile Dermatomyositis Response to Rituximab

Amer khojah1,2, Victoria Hans3, Wilfredo Marin4, Gabrielle A. Morgan4 and Lauren M. Pachman5,6,7, 1Division of Pediatric Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 2Division of Pediatric Allergy Immunology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 3Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 4Cure JM Program of Excellence in Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, 5Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, 6Pediatric Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 7Rheumatology/Immunology, Ann & Robert H. Lurie Children's Hosptial of Chicago, Chicago, IL

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: B cells, BAFF, juvenile dermatomyositis and rituximab

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: B Cell Biology and Targets in Autoimmune and Inflammatory Disease Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Rituximab is used for the treatment of juvenile dermatomyositis (JDM) with variable success. Some of this variability is presumed to be related to the effectiveness of tissue B cell depletion. Forming new B cells requires B cell receptor recombination and the formation of KREC. The KREC does not replicate with B cell divisions. The recombination site on chromosomal DNA is known as the joining code (JC). The ratio of JC: KREC determined by qRT-PCR estimates the number of B cell divisions that have occurred in a B cell population. BAFF is a cytokine produced by activated macrophages and dendritic cell to promote B cell survival and proliferation. We hypothesized that Rituximab treated JDM who have near complete tissue B cell depletion will have a low JC to KRECs ratio and increased soluble BAFF level, which is associated with a more effective response to Rituximab.

Methods:

This is an IRB approved, retrospective pilot study conducted at Lurie Children’s Hospital. We included 9 JDM patients (mean age 12.5 ± 2.2 years). Their  demographics are presented in Table 1. We measured JC and KREC qRT-PCR from serial PBMC stored (-80oC) in the CureJM Center Repository. BAFF level was measured using Mesoscale® technology. We defined oligoclonal B cell expansion as a JC:KRECs ratio of 8 or more before Rituximab therapy. A JC:KREC ratio of 2.5 or less on the first detectable sample post-Rituximab was considered as an evidence of good B cell depletion. A good response to therapy was defined as improvement of the Disease Activity Score (DAS) by at least 2 points on two consecutive visits. This study is supported by a grant from CARRA. 

Results:

6 out 9 JDM had evidence of oligoclonal B cell expansion prior to Rituximab use. Of those 6 subjects, 4 had good B cell depletion and responded well to Rituximab therapy. On the other hand, 1 out of 2 subjects with poor B cells depletion had a lack of response to Rituximab. All JDM without oligoclonal B cell expansion had a poor response to Rituximab therapy (Table 1). Although serum BAFF level increased in almost all subjects after Rituximab therapy, subjects with poor B cell depletion appeared to have only a minor increase (Fig 1). 

Conclusion:

Children with JDM who demonstrate oligoclonal B cell expansion prior to the use of Rituximab have a more favorable outcome. If this finding is confirmed, KREC PCR may serve as a selection criterion for Rituximab therapy. BAFF levels increase after Rituximab therapy, which may contribute to disease flare and may provide a therapeutic target.  Limitations of this pilot study include the low numbers of subjects, which requires validation in additional cohorts. 


Disclosure: A. khojah, None; V. Hans, None; W. Marin, None; G. A. Morgan, None; L. M. Pachman, None.

To cite this abstract in AMA style:

khojah A, Hans V, Marin W, Morgan GA, Pachman LM. Kappa-Deleting Recombination Excision Circles (KREC) in B Cells and Serum B Cell Activating Factor (BAFF): Possible Aids in Predicting Juvenile Dermatomyositis Response to Rituximab [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/kappa-deleting-recombination-excision-circles-krec-in-b-cells-and-serum-b-cell-activating-factor-baff-possible-aids-in-predicting-juvenile-dermatomyositis-response-to-rituximab/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/kappa-deleting-recombination-excision-circles-krec-in-b-cells-and-serum-b-cell-activating-factor-baff-possible-aids-in-predicting-juvenile-dermatomyositis-response-to-rituximab/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology